Diagnostic methods are not certified in this packet. The definition notes characteristic tumor-cell features, namely polygonal, deeply eosinophilic cells within a fibrous stroma.

No foundational therapies, approved treatments, or management guidance specific to this condition are certified in this packet, so the absence of such information here does not indicate that none exist. Investigational approaches appear in the listed clinical trial records, which include studies of immune checkpoint inhibitor combinations, a peptide vaccine, and a glutamine antagonist combined with an immunotherapy.

Prognosis is not certified in this packet. The ontology definition states that the prognosis is similar to classical hepatocellular carcinoma arising in non-cirrhotic livers and better than hepatocellular carcinoma arising in cirrhotic livers.

Several active clinical trial records are certified for this condition. Examples include NCT06027086, a Phase 1 study of DRP-104 in combination with durvalumab in advanced fibrolamellar carcinoma (active, not recruiting); NCT04380545, a Phase 1 study of nivolumab, fluorouracil, and interferon alpha 2B in unresectable fibrolamellar cancer (recruiting); and NCT04134559, a Phase 2 study of checkpoint inhibition in pediatric hepatocellular carcinoma (recruiting). Active clinical trials for this condition are listed on ClinicalTrials.gov.